Lixte Financial Statements From 2010 to 2025

LIXT Stock  USD 1.20  0.02  1.64%   
Lixte Biotechnology financial statements provide useful quarterly and yearly information to potential Lixte Biotechnology Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lixte Biotechnology financial statements helps investors assess Lixte Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lixte Biotechnology's valuation are summarized below:
Market Capitalization
3.3 M
Earnings Share
(1.73)
There are currently one hundred eighteen fundamental ratios for Lixte Biotechnology that can be evaluated and compared over time across peers in the industry. All traders should check Lixte Biotechnology's last-minute fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 881.5 K in 2025. Enterprise Value is likely to gain to about (5 M) in 2025
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 19.6 K, Other Operating Expenses of 6.1 M or EBITDA of 3.9 K, as well as many indicators such as Price To Sales Ratio of 56.09, Dividend Yield of 2.0E-4 or PTB Ratio of 1.06. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Lixte Biotechnology Correlation against competitors.

Lixte Biotechnology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.2 MM2.7 M
Slightly volatile
Other Current Liabilities379 K360.9 K172.2 K
Slightly volatile
Total Current Liabilities290.7 K360.9 K276.6 K
Slightly volatile
Cash5.1 M4.8 M2.5 M
Slightly volatile
Cash And Short Term Investments5.1 M4.8 M2.5 M
Slightly volatile
Common Stock Shares Outstanding1.6 M1.7 M40.4 M
Slightly volatile
Liabilities And Stockholders Equity5.2 MM2.7 M
Slightly volatile
Other Stockholder Equity59.1 M56.3 M27.2 M
Slightly volatile
Total Liabilities290.7 K360.9 K276.6 K
Slightly volatile
Total Current Assets5.1 M4.9 M2.7 M
Slightly volatile
Common Stock2462593.2 K
Slightly volatile
Property Plant And Equipment Net109115184
Slightly volatile
Accounts Payable169.4 K180.3 K165.5 K
Slightly volatile
Other Current Assets29.6 K31.2 K77.3 K
Slightly volatile
Common Stock Total Equity4.2 MM1.4 M
Slightly volatile
Short and Long Term Debt Total80 K90 K98.1 K
Slightly volatile
Short Term Debt193.4 K360.9 K195 K
Slightly volatile
Net Receivables12.3 K12.9 K78.5 K
Slightly volatile
Inventory58.1 K70.1 K60.3 K
Slightly volatile
Current Deferred Revenue189.7 K180.7 K80.5 K
Slightly volatile
Preferred Stock Total Equity3.2 MM2.9 M
Slightly volatile
Net Working Capital4.2 M4.6 M2.6 M
Slightly volatile
Deferred Long Term Liabilities1.8 K2.1 K2.3 K
Slightly volatile
Capital Stock2.8 M3.2 M3.4 M
Slightly volatile

Lixte Biotechnology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses6.1 M5.9 M3.3 M
Slightly volatile
Total Operating Expenses6.1 M5.9 M3.3 M
Slightly volatile
Depreciation And Amortization6.1 M5.9 M2.1 M
Slightly volatile
Selling General Administrative5.1 M4.8 M2.3 M
Slightly volatile
Research DevelopmentMMM
Pretty Stable
Interest Income12.9 K23.6 K8.2 K
Slightly volatile
Selling And Marketing Expenses3.4 M3.8 M4.1 M
Slightly volatile

Lixte Biotechnology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities2.5 M3.6 M2.8 M
Slightly volatile
End Period Cash Flow5.1 M4.8 M2.5 M
Slightly volatile
Begin Period Cash Flow6.5 M6.2 M2.4 M
Slightly volatile
Depreciation109115147
Slightly volatile
Stock Based Compensation858.4 K889.2 K846 K
Slightly volatile
Dividends Paid1.7 K1.8 K8.1 K
Slightly volatile
Other Cashflows From Investing Activities86.2 K93.7 K104.4 K
Slightly volatile
Change To Netincome1.2 M1.8 M1.2 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio56.0963.168.7956
Slightly volatile
Dividend Yield2.0E-43.0E-42.0E-4
Slightly volatile
Average Payables117.9 K184.4 K164 K
Slightly volatile
Stock Based Compensation To Revenue2.22.472.6968
Slightly volatile
Capex To Depreciation0.850.530.5269
Very volatile
EV To Sales55.9862.9968.6713
Slightly volatile
Sales General And Administrative To Revenue3.023.393.7013
Slightly volatile
Research And Ddevelopement To Revenue8.379.4110.2636
Slightly volatile
Cash Per Share2.371.983.7858
Slightly volatile
Income Quality0.540.760.7013
Very volatile
Current Ratio12.9712.369.1027
Slightly volatile
Capex Per Share0.00.00.0
Very volatile
Average Receivables7.8 K8.3 K13.7 K
Slightly volatile
Revenue Per Share0.210.230.2521
Slightly volatile
Interest Debt Per Share0.0530.05050.0147
Slightly volatile
Debt To Assets1.551.741.8996
Slightly volatile
Ebt Per Ebit1.161.151.0812
Pretty Stable
Quick Ratio12.9712.369.0894
Slightly volatile
Net Income Per E B T0.790.90.9678
Slightly volatile
Cash Ratio12.6612.058.4421
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.016
Slightly volatile
Debt Ratio1.551.741.8996
Slightly volatile
Price Sales Ratio56.0963.168.7956
Slightly volatile
Asset Turnover0.260.30.3277
Slightly volatile

Lixte Biotechnology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap881.5 K927.9 K25.8 M
Slightly volatile

Lixte Fundamental Market Drivers

Cash And Short Term Investments4.2 M

Lixte Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Lixte Biotechnology Financial Statements

Lixte Biotechnology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Lixte Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Lixte Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lixte Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue180.7 K189.7 K
Stock Based Compensation To Revenue 2.47  2.20 
Sales General And Administrative To Revenue 3.39  3.02 
Research And Ddevelopement To Revenue 9.41  8.37 
Revenue Per Share 0.23  0.21 
Ebit Per Revenue(11.91)(12.50)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.